image credit: Unsplash

Bristol Myers Squibb-backed Clade nabs a meaty $87M series A for cell therapy 2.0

November 3, 2021

It still feels as if the use of cell therapy is a fresh innovation, but inertia is the enemy of progress, and next-gen approaches are already here.

One biotech among a growing pack is the newly uncloaked Clade Therapeutics, which has brought in an impressive $87 million initial funding round led by Syncona with help from LifeSci Venture Partners, Emerson Collective and Bristol Myers Squibb.

Read More on FierceBiotech